Provided by Tiger Trade Technology Pte. Ltd.

Abbott Laboratories

103.38
+1.431.40%
Volume:1.95M
Turnover:201.47M
Market Cap:179.76B
PE:33.45
High:104.44
Open:104.00
Low:103.01
Close:101.95
52wk High:137.49
52wk Low:81.97
Shares:1.74B
Float Shares:1.70B
Volume Ratio:0.61
T/O Rate:0.11%
Dividend:2.48
Dividend Rate:2.40%
EPS(TTM):3.09
EPS(LYR):3.73
ROE:10.58%
ROA:5.33%
PB:3.52
PE(LYR):27.71

Loading ...

Movement Alert|Abbott Laboratories Rises 3.21% in Regular Trading, FDA Approval of Colorectal Cancer Blood Screening Test Continues to Boost Shares

Market Focus
·
Aug 03

Perrigo Co. PLC Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

Abitare In closes €141 million project sale and seeks exit from STAR segment

TIPRANKS
·
Jul 31

Abbott Laboratories Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 31

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26

TIPRANKS
·
Jul 31

Movement Alert|Abbott Laboratories Falls 3.08% in Regular Trading, Multiple Banks Cut Target Prices Triggering Pullback Pressure

Market Focus
·
Jul 30

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 30

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

Abbott Labs is Maintained at Buy by UBS

Dow Jones
·
Jul 29

Movement Alert|Abbott Laboratories Rises 3.07% in Regular Trading, FDA Approves Its Exclusive Colorectal Cancer Blood Screening Test

Market Focus
·
Jul 28

Abbott price target lowered to $125 from $135 at UBS

TIPRANKS
·
Jul 28

Rothschild & Co Redburn Adjusts PT on Abbott Laboratories to $119 From $126, Maintains Neutral Rating

MT Newswires Live
·
Jul 28

Abitare In Publishes 2025 Sustainability Report, Underscoring Urban Regeneration Strategy

TIPRANKS
·
Jul 28

Leah Bennett: Where to Invest After the AI-Chip Stock Surge

Dow Jones
·
Jul 27

Freenome, Abbott Laboratories' Colorectal Cancer Screening Test Approved by FDA; Freenome Earns $100 Million Milestone Payment

MT Newswires Live
·
Jul 27

US Companies Face Rise in Cyber Attacks

Reuters
·
Jul 27

FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott to Commercialize in the U.S.

Reuters
·
Jul 27

Freenome, Abbott announce FDA approval of SimpleScreen CRC

TIPRANKS
·
Jul 27

Freenome- Freenome to Receive $100 Mln Milestone Payment from Abbott for FDA Approval

THOMSON REUTERS
·
Jul 27